Research Unit of Neurology, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo, 21 - 00128 Rome, Italy; Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200 - 00128 Rome, Italy.
Radiology and Neuroradiology Unit, Department of Imaging, Radiation Therapy and Hematology, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
J Stroke Cerebrovasc Dis. 2024 Aug;33(8):107819. doi: 10.1016/j.jstrokecerebrovasdis.2024.107819. Epub 2024 Jun 13.
Stump syndrome is defined as a clinical syndrome resulting from a distal intracranial vessel embolic stroke due to an extracranial vessel occlusion. Similar to the anterior circulation, the recurrence of ischemic strokes in territories supplied by the posterior circulation in the presence of vertebral artery occlusion is termed Vertebral Artery Stump Syndrome (VASS).
We conducted a literature review, identifying 72 patients with transient ischemic attacks (TIAs) or ischemic strokes attributed to VASS, according to Kawano criteria. We categorized all patients in two groups focusing on the therapeutic management those who underwent primary medical treatment and those who received endovascular or surgical treatment either in acute or chronic phase.
In the anticoagulant therapy group, only 1 patient had a stroke recurrence. Among the 4 on antiplatelets, all had recurrences, but 3 benefited from switching to anticoagulants or endovascular therapy. In the endovascular therapy group, worse outcomes were linked to acute large vessel occlusion. Endovascular treatment of the vertebral artery, in a chronic phase, was explored in literature for recurrent TIAs or minor strokes suggesting that this could be a viable therapeutic alternative when medical treatment failed in preventing recurrence of ischemic stroke.
Some studies suggest that anticoagulant medical therapy may be beneficial for VASS and endovascular therapy has also been reported for selected patients. However, data on treatment outcomes and prognosis are still underreported, making treatment decisions challenging. Randomized Controlled Trials are needed to establish the optimal treatment approach.
残端综合征定义为由于颅外血管阻塞导致的远端颅内血管栓塞性卒中引起的临床综合征。与前循环类似,在后循环供血区存在椎动脉闭塞的情况下,发生缺血性卒中复发被称为椎动脉残端综合征(VASS)。
我们进行了文献回顾,根据川野标准,确定了 72 例归因于 VASS 的短暂性脑缺血发作(TIA)或缺血性卒中患者。我们将所有患者分为两组,重点关注治疗管理,一组接受了主要的药物治疗,另一组在急性或慢性阶段接受了血管内或手术治疗。
在抗凝治疗组中,仅有 1 例患者发生卒中复发。在接受抗血小板治疗的 4 例患者中,所有患者均有复发,但其中 3 例通过转换为抗凝或血管内治疗获益。在血管内治疗组中,急性大血管闭塞与较差的结局相关。在慢性阶段对椎动脉进行血管内治疗的方法在文献中被探讨用于复发性 TIA 或轻度卒中,表明当药物治疗未能预防缺血性卒中复发时,这可能是一种可行的治疗选择。
一些研究表明抗凝药物治疗可能对 VASS 有益,血管内治疗也已被报道用于某些患者。然而,关于治疗结果和预后的数据仍然报告不足,使得治疗决策具有挑战性。需要进行随机对照试验来确定最佳的治疗方法。